20:29 , Jul 6, 2018 |  BC Extra  |  Company News

Management tracks: Goldman Sachs, Acceleron

One of China's top healthcare analysts, Richard Yeh, said he is departing Goldman Sachs, where he was in global investment research for Asia Pacific. Several Asia-focused bankers and analysts, including Citigroup's Billy Cho, Bank of...
03:05 , Jun 30, 2018 |  BioCentury  |  Finance

Hidden in the rough

Judicious stock picking was especially important in the second quarter, as 57% of global biotech stocks saw their equity values decline. Volatility continued to roil global markets during the period and additional uncertainty looms with the...
18:49 , Apr 20, 2018 |  BC Week In Review  |  Clinical News

CHMP rebuffs AB Science’s masitinib in ALS

EMA’s CHMP recommended against approval of masitinib (AB1010) from AB Science S.A. (Euronext:AB) to treat amyotrophic lateral sclerosis. The company said it plans to address the issues raised by the committee and expects a second...
22:56 , Apr 19, 2018 |  BC Extra  |  Company News

CHMP rebuffs AB Science’s masitinib in ALS

EMA’s CHMP recommended against approval of masitinib (AB1010) from AB Science S.A. (Euronext:AB) to treat amyotrophic lateral sclerosis. The company said it plans to address the issues raised by the committee and expects a second...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
23:52 , Oct 6, 2017 |  BioCentury  |  Finance

Bargain shopping

With all companies valued over $1 billion increasing a median of at least 16.8% in 1H17, investors went bargain shopping in the $500-$999 million tier in 3Q17. The group outperformed all other market cap bands,...
20:19 , Sep 22, 2017 |  BC Week In Review  |  Clinical News

CHMP issues second recommendation against AB Science's masitinib

EMA's CHMP for the second time recommended against approval of a resubmitted MAA from AB Science S.A. (Euronext:AB) for Masipro masitinib (Masiviera, Masican, AB1010) to treat systemic mastocytosis in adults. CHMP's concerns echoed those of...
23:51 , Sep 15, 2017 |  BC Extra  |  Company News

CHMP issues negative opinions

On Friday, EMA's CHMP issued negative opinions for a number of products, including Duchenne muscular dystrophy candidate Raxone idebenone (SNT-MC17) from Santhera Pharmaceuticals Holding AG (SIX:SANN). CHMP also said Bristol-Myers Squibb Co. (NYSE:BMY) withdrew an...
00:20 , Jul 8, 2017 |  BioCentury  |  Finance

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...
17:21 , May 26, 2017 |  BC Week In Review  |  Clinical News

AB Science reports masitinib data in Phase II/III ALS trial

AB Science S.A. (Euronext:AB) reported additional data from the double-blind, Spanish Phase II/III Study AB10015 suggesting that the higher of 2 doses of oral masitinib (Masican, Masiviera) (AB1010) significantly slowed the progression of amyotrophic lateral...